Metis Global Partners LLC Raises Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Metis Global Partners LLC lifted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 13,697 shares of the company’s stock after acquiring an additional 860 shares during the period. Metis Global Partners LLC’s holdings in Teva Pharmaceutical Industries were worth $302,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Stifel Financial Corp lifted its holdings in shares of Teva Pharmaceutical Industries by 54.0% during the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after purchasing an additional 23,283 shares during the period. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Teva Pharmaceutical Industries by 7.2% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock worth $10,983,000 after purchasing an additional 33,277 shares during the period. Thrivent Financial for Lutherans lifted its holdings in shares of Teva Pharmaceutical Industries by 21.8% during the third quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock worth $4,046,000 after purchasing an additional 40,218 shares during the period. Sio Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth about $24,314,000. Finally, Pinnbrook Capital Management LP acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $4,966,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares in the company, valued at $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Stock Down 3.6 %

Shares of TEVA opened at $15.32 on Friday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a one year low of $12.51 and a one year high of $22.80. The stock has a market capitalization of $17.37 billion, a price-to-earnings ratio of -10.57, a PEG ratio of 1.44 and a beta of 0.71. The stock has a 50 day moving average price of $19.00 and a 200 day moving average price of $18.40.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TEVA. Barclays decreased their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. UBS Group decreased their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Finally, Bank of America reduced their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.